Bad news from the FDA for Dendreon Corp. on Provenge for prostate cancer sent the firm's stock into a tailspin and trimmed other cancer-vaccine companies' shares as well, taking away some of the gains made when an advisory panel gave the compound a positive vote in late March. (BioWorld Today)